Krystal Biotech (KRYS) Short-term Investments (2018 - 2026)

Krystal Biotech has reported Short-term Investments for 9 years, with the latest figure at $417.9 million in Q2 2026.

• Short-term Investments for Q2 2026 came in at $417.9 million, up 27.34% year-over-year; the trailing twelve-month figure through Jun 2026 was $417.9 million (up 27.34% YoY), and the FY2025 annual result was $331.5 million, up 31.2% from the prior year.
• Short-term Investments grew to $417.9 million in Q2 2026, from $322.1 million in the prior quarter.
• Over five years, Short-term Investments peaked at $417.9 million in Q2 2026 and troughed at $165.3 million in Q1 2022.
• A 5-year average of $248.8 million and a median of $214.1 million in 2024 frame the typical range for Short-term Investments.
• The widest annual swing landed in 2022, when Short-term Investments surged 13147.52%; it then dropped 19.98% in 2023.
• A 5-year view of Short-term Investments shows it stood at $217.3 million in 2022, then dropped by 19.98% to $173.8 million in 2023, then jumped by 45.33% to $252.7 million in 2024, then surged by 31.2% to $331.5 million in 2025, then advanced by 26.07% to $417.9 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $417.9 million in Q2 2026, $322.1 million in Q1 2026, and $331.5 million in Q4 2025.